Axonics has patented a composition containing stem cells, a cell culture medium, and a polyacrylamide hydrogel with specific properties. This composition is designed for injection and aims to prevent or treat tendon injuries, arthritis, or arthropathy in mammals, including humans and animals. GlobalData’s report on Axonics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Axonics, Neuromodulation implants was a key innovation area identified from patents. Axonics's grant share as of May 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Composition for stem cell therapy in tendon injury treatment
A recently granted patent (Publication Number: US11969523B2) discloses a composition comprising stem cells, a cell culture medium, and a polyacrylamide hydrogel. The polyacrylamide hydrogel includes acrylamide monomers, a cross-linking agent, and N-hydroxyethyl acrylamide (HEA), with a specific weight percent of HEA. The elasticity modulus of the polyacrylamide hydrogel ranges from 1 to 200 Pa, encapsulating mesenchymal stem cells to support their viability and proliferation. The molar ratio of acrylamide monomers to the cross-linking agent is crucial, falling between 150:1 to 1000:1, ensuring the effectiveness of the composition.
Furthermore, the patent claims cover various aspects of the composition, including the elasticity modulus of the polyacrylamide hydrogel, the dry matter content, and the specific cross-linking agent used. The patent also outlines a detailed process for making the composition, involving the encapsulation of mesenchymal stem cells in the polyacrylamide hydrogel to support their functionality. Additionally, methods for incorporating the composition into a pharmaceutical formulation suitable for human administration and for improving tendon injuries in mammals, including humans, racing mammals like horses, and companion mammals like dogs, are also disclosed. The administration of the composition through injection is highlighted as a preferred method for treating tendon injuries effectively.
To know more about GlobalData’s detailed insights on Axonics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
